Skip to content

Medical billing • Healthcare policy • Practical education

Our editorial standards

HCPCS Code J3301 Explained: Triamcinolone Acetonide Billing Units, Injection Coding, JW/JZ Modifiers, and 2026 Medicare Rules

By David Bennett 22 min read

A steroid injection can look simple on the clinical side: the drug is selected, a dose is drawn up, and the medication is injected. Billing is less forgiving. The claim has to translate the amount administered into the billing unit defined by the HCPCS code, connect the drug to the correct administration service, and handle waste correctly when Medicare’s JW or JZ rules apply.

That is where J3301 causes trouble. It is often searched as “CPT code J3301,” but J3301 is actually a HCPCS Level II drug code. CMS identifies J3301 as triamcinolone acetonide injection, not otherwise specified, reported in 10 mg billing units. The phrase “10 mg” is the part that matters most when the charge is built.

A 40 mg injection is not one J3301 unit simply because one injection occurred. If J3301 is the correct drug code, 40 mg equals four billing units. The volume in the syringe may be 1 mL, 4 mL, or something else depending on the product concentration. Volume and HCPCS units answer different questions.

The product also matters. Triamcinolone acetonide is available in different formulations and package sizes, including single-dose and multiple-dose vials. Some triamcinolone products have their own HCPCS codes rather than J3301. That means billing teams should identify the exact medication before converting the dose into units.

CMS continues to publish quarterly Medicare Part B drug payment-limit files and NDC-HCPCS crosswalks in 2026. Medicare’s discarded-drug policy also requires JW or JZ reporting for qualifying drugs from single-dose containers or single-use packages. For J3301, those rules cannot be applied by habit because triamcinolone acetonide products can be supplied in both single-dose and multiple-dose containers.

J3301 at a Glance

Question Practical answer
What is J3301? A HCPCS Level II code for triamcinolone acetonide injection, not otherwise specified.
What is one billing unit? 10 mg.
Does J3301 include the injection procedure? No. The drug and the administration service are separate coding questions.
Is 40 mg one unit? No. If J3301 applies, 40 mg equals 4 units.
Does concentration determine units? No. Units are based on total milligrams represented by the HCPCS descriptor.
Are JW and JZ always required? No. They apply to qualifying separately payable Part B drugs from single-dose containers or single-use packages; multiple-dose containers are treated differently.
Is one triamcinolone product interchangeable with another for billing? No. Product formulation and the specific HCPCS descriptor must match.
Is the Medicare payment amount fixed for the year? No. CMS publishes Part B drug payment-limit files quarterly.

 

What Is HCPCS Code J3301?

J3301 is a HCPCS Level II code used to report triamcinolone acetonide injection when the product is not otherwise described by a more specific HCPCS code. The CMS Medicare Physician and Other Practitioner data tool lists the code as triamcinolone acetonide injection, not otherwise specified, with a billing increment of 10 mg.

That wording creates two separate jobs for the billing team. First, confirm that J3301 actually matches the product that was administered. Second, convert the documented dose into 10 mg units.

The code describes the drug, not the act of injecting it. A claim can therefore include J3301 and, when separately reportable and supported, an administration or procedure code describing how the medication was given.

For a broader look at how a drug charge moves from documentation to a payer claim, MedIntelHub’s medical billing workflow from visit to payment explains the larger charge-capture and adjudication process.

Is J3301 a CPT Code or a HCPCS Code?

J3301 is a HCPCS Level II code, not a CPT code.

The distinction is more than terminology. CPT is maintained by the American Medical Association and includes professional services and procedures. HCPCS Level II includes many drugs, biologicals, supplies, and other items used for Medicare and other payer billing.

J-codes are commonly used for injectable drugs that are typically administered in a physician office, hospital outpatient department, or other covered setting. The letter-number format makes them look different from five-digit CPT procedure codes, but search engines still surface phrases such as “CPT J3301” because that is how many people search.

For the claim itself, use the current HCPCS description and payer instructions rather than the shorthand used in a search box.

What Drug Does J3301 Represent?

J3301 represents triamcinolone acetonide injection that is not otherwise specified by a different HCPCS code. Triamcinolone acetonide is a corticosteroid used in a number of clinical settings, but the billing code does not tell the clinician which product, route, or dose to choose.

Those clinical decisions come from the prescription, product labeling, patient circumstances, and professional judgment. Billing should follow the service that was actually performed.

DailyMed illustrates why the exact product matters. KENALOG-10 is a 10 mg/mL triamcinolone acetonide suspension labeled for intra-articular or intralesional use only. Other triamcinolone acetonide injectable suspensions are supplied at 40 mg/mL and may be labeled for intramuscular or intra-articular use. Some 40 mg/mL products are available as a 1 mL single-dose vial and also in larger multiple-dose vials.

A coder should not infer route or package type from the words “triamcinolone injection” alone. The medication administration record, order, lot/product information, and package used at the encounter are more reliable sources.

How Many Milligrams Equal One J3301 Unit?

One J3301 billing unit represents 10 mg of triamcinolone acetonide.

The unit calculation is therefore straightforward once the administered dose is known:

J3301 units = total milligrams administered / 10 mg

The math is simple. The error usually happens when a practice confuses the number of injections, the number of vials, or the volume in milliliters with the HCPCS billing quantity.

10 mg Example

A patient receives 10 mg of a triamcinolone acetonide product correctly reported with J3301.

10 mg / 10 mg per unit = 1 unit of J3301.

20 mg Example

A documented dose of 20 mg converts to:

20 mg / 10 mg per unit = 2 units of J3301.

40 mg Example

A documented dose of 40 mg converts to:

40 mg / 10 mg per unit = 4 units of J3301.

This is one of the most common places for underbilling. A 40 mg dose may come from a single 1 mL vial of a 40 mg/mL product, but the HCPCS claim quantity is still four units because the code is measured in 10 mg increments.

80 mg Example

An 80 mg dose converts to:

80 mg / 10 mg per unit = 8 units of J3301.

The dose must be clinically ordered and documented. The billing calculation does not determine what dose should be given.

Why Drug Concentration Is Different From HCPCS Units

Concentration answers, “How much drug is in each milliliter?” The HCPCS descriptor answers, “How much drug does one claim unit represent?”

Those are different measurements.

Consider two hypothetical products that both qualify for J3301:

Product concentration Volume administered Total dose J3301 units
10 mg/mL 1 mL 10 mg 1
40 mg/mL 0.25 mL 10 mg 1
40 mg/mL 1 mL 40 mg 4
40 mg/mL 2 mL 80 mg 8

 

The same 10 mg dose can come from different volumes. The claim quantity is still one J3301 unit if the drug code is correct.

This is also why a charge master should not simply map “one syringe” or “one vial” to one unit. The dose field and product concentration need to support the conversion.

J3301 and Triamcinolone Product Selection

J3301 contains the words “not otherwise specified.” That should prompt a product check before the code is assigned.

CMS lists several distinct HCPCS codes within the broader triamcinolone family. For example, J3300 describes preservative-free triamcinolone acetonide in a 1 mg unit, J3304 describes a preservative-free extended-release microsphere formulation in a 1 mg unit, and J3299 is used for the Xipere formulation. Other codes identify different triamcinolone compounds such as diacetate or hexacetonide.

The practical rule is simple: do not choose J3301 merely because the active ingredient contains the word triamcinolone. Match the exact product and formulation to the current HCPCS descriptor.

A product-specific code can affect more than the code number. It may carry a different billing unit, price, coverage policy, route, or payer edit.

J3301 vs. Other Triamcinolone HCPCS Codes

The table below is a high-level orientation, not a substitute for the current HCPCS file or payer policy.

HCPCS code General distinction
J3301 Triamcinolone acetonide injection, not otherwise specified, per 10 mg
J3300 Preservative-free triamcinolone acetonide, per 1 mg
J3304 Preservative-free extended-release microsphere triamcinolone acetonide, per 1 mg
J3299 Triamcinolone acetonide formulation marketed as Xipere, per 1 mg
J3302 Triamcinolone diacetate injection
J3303 Triamcinolone hexacetonide injection

 

Because these codes do not all represent the same product or billing increment, swapping them based on price or convenience is not appropriate.

Does J3301 Include the Injection Procedure?

No. J3301 represents the drug.

The work of administering that drug may be separately reported when the circumstances, documentation, CPT rules, NCCI edits, and payer policy support a separate administration service.

For example, a practice may administer triamcinolone intramuscularly, inject it into a joint, or use a product labeled for intralesional treatment. Those are not the same administration service, and the procedure code should reflect what actually happened.

A useful way to think about the claim is to separate three questions:

  1. What drug was supplied? That determines the drug HCPCS code.
  2. How much drug was administered? That determines the HCPCS units.
  3. How was the drug administered? That determines whether an administration or procedural service is separately reportable.

The drug code should not be used as a shortcut for the procedure, and the procedure code should not be expected to communicate the drug dose.

Which Administration Codes May Be Reported With J3301?

There is no single administration code that always accompanies J3301. The correct procedure depends on the route, site, service, and documentation.

Intramuscular Injection

For an intramuscular therapeutic injection, a code such as 96372 may be relevant when the service meets current CPT and payer requirements.

The chart should identify the medication, dose, route, site, and who performed the administration. Product labeling matters here as well. A formulation labeled only for intra-articular or intralesional use should not be treated as an intramuscular product simply because the active ingredient is the same.

Joint Injection

When triamcinolone is administered during aspiration or injection of a joint or bursa, the procedure code depends on the anatomical site and whether image guidance is part of the reported service.

Common joint-injection families distinguish small, intermediate, and major joints, with separate ultrasound-guided variants. The drug and the procedure are still separate components of the claim.

Intralesional Injection

Dermatology and other specialties may use an intralesional injection service when medication is injected directly into a lesion and the product labeling supports that route.

Again, the HCPCS units describe the drug quantity, while the procedure code describes the work performed.

Because CPT administration codes and bundling rules can change, practices should verify the current CPT code set, NCCI edits, and payer policy rather than building a permanent J3301-to-procedure mapping.

What Documentation Supports J3301?

A strong drug note should make the claim understandable without forcing a reviewer to guess what was used.

Useful documentation typically includes:

  • Drug name and formulation
  • Dose administered in milligrams
  • Concentration when relevant to the dose calculation
  • Route of administration
  • Anatomical site when relevant
  • Number of sites or joints when that affects procedure coding
  • Date of administration
  • Ordering or prescribing information as required
  • Product/NDC information when required by the payer or practice policy
  • Amount discarded when a single-dose-container waste rule applies
  • Package type when needed to support JW/JZ reporting
  • Associated diagnosis or clinical reason for treatment

A line that says only “Kenalog injection given” may be too vague for reliable billing. It does not tell the billing team how many milligrams were administered, which formulation was used, or whether the vial was single-dose or multiple-dose.

What Diagnosis Code Should Be Used With J3301?

There is no single universal ICD-10-CM diagnosis code for J3301.

The diagnosis should reflect the documented condition being treated and should be consistent with the administration service and medical necessity requirements that apply to the payer.

A joint injection for an inflammatory or degenerative joint condition will not necessarily use the same diagnosis coding as an intralesional injection for a dermatologic condition. Likewise, a systemic intramuscular steroid injection can involve an entirely different clinical reason.

The diagnosis should come from the patient’s documented condition, not from the drug name alone.

If a payer has a local coverage determination, billing article, or utilization policy for the procedure or injected drug, review the current version before relying on an old diagnosis list.

J3301 and Medical Necessity

A valid HCPCS code does not guarantee payment.

The record still has to show why the medication and administration service were medically necessary for that patient on that date. Coverage can depend on the diagnosis, route, frequency, prior treatment, setting, and payer-specific rules.

The drug dose must also make clinical sense in the context of the order and product labeling. Billing staff should not alter the units to fit a payer edit or expected reimbursement. If the documentation and the charge do not agree, the discrepancy should be resolved before the claim is submitted.

MedIntelHub’s claim denials prevention and follow-up checklist includes a broader workflow for reviewing units, modifiers, documentation, and payer edits before a claim leaves the practice.

J3301 and NDC Reporting

NDC reporting is payer-specific.

Some Medicaid programs and commercial plans require the National Drug Code in addition to the HCPCS code. Medicare Part B also uses NDC-HCPCS crosswalks for drug pricing and payment policy, but providers should not assume that every payer wants the same NDC format or unit-of-measure convention on the claim.

When an NDC is required, billing staff should verify:

  • The exact product package used
  • The payer’s required NDC format
  • The appropriate NDC qualifier
  • The unit of measure required by that payer
  • The quantity reported in NDC units
  • That the NDC corresponds to the HCPCS code and product actually administered

HCPCS units and NDC units are not interchangeable. A claim may legitimately show four units of J3301 while the NDC quantity is reported using a different unit-of-measure convention.

Do not derive an NDC from a favorite product in the charge master if the medication was supplied from a different package.

J3301 With JW and JZ Modifiers

The JW and JZ modifiers address drug waste under Medicare Part B, but they do not automatically belong on every J3301 claim.

CMS requires JW or JZ reporting for separately payable Part B drugs furnished from qualifying single-dose containers or single-use packages. The package actually used is therefore central to the decision.

That matters for triamcinolone acetonide because current product labeling shows both single-dose and multiple-dose vial configurations for some 40 mg/mL products.

When JW May Apply

JW is used to report the amount of a qualifying drug that was unused and discarded from a single-dose container or single-use package.

CMS instructs providers to report the administered amount on one claim line without JW and the discarded amount on a separate line with JW. Payment is subject to the applicable Medicare rules and the amount available in the labeled container.

Example: a single-dose vial contains 40 mg. If 30 mg is administered and 10 mg is discarded, and J3301 is the correct drug code, the administered amount equals three J3301 units and the discarded amount equals one J3301 unit. The waste line would carry JW when Medicare’s single-dose-container policy applies.

That example is about claim math, not a dosing recommendation.

When JZ May Apply

JZ is used to attest that no amount was discarded from a qualifying single-dose container or single-use package.

If 40 mg is administered from a qualifying 40 mg single-dose vial and nothing is discarded, the claim may report four J3301 units with JZ when Medicare’s policy applies.

CMS states that JZ is required on claims for separately payable Part B drugs from single-dose containers or single-use packages when there is no discarded amount.

Why Multiple-Dose Vials Matter

JW and JZ are tied to single-dose containers and single-use packages. They are not the same kind of requirement for a multiple-dose vial.

DailyMed currently lists examples of triamcinolone acetonide 40 mg/mL supplied as a 1 mL single-dose vial as well as 5 mL and 10 mL multiple-dose vials. A billing system that looks only at the HCPCS code and ignores package type can therefore apply the wrong modifier logic.

The safest workflow is to identify the actual package used at the encounter before deciding whether JW, JZ, or neither is appropriate.

Single-Dose and Multiple-Dose Vials: A Billing Example

Suppose a practice stocks two versions of a 40 mg/mL triamcinolone acetonide suspension:

  • 1 mL single-dose vial containing 40 mg
  • 5 mL multiple-dose vial containing 200 mg total

A 20 mg administered dose equals two J3301 units in either case if J3301 is the correct drug code.

The difference is the discarded-drug analysis. With the single-dose vial, any unused amount may trigger JW reporting, or JZ may be required if there is no waste. With the multiple-dose vial, the single-dose-container JW/JZ rule does not apply in the same way.

The HCPCS unit calculation stayed the same. The modifier decision changed because the package changed.

2026 Medicare Part B Drug Pricing for J3301

There is no single J3301 payment number that should be hard-coded for all of 2026.

CMS publishes Medicare Part B drug payment-limit files quarterly. As of September 2026, CMS has posted January, April, and July 2026 files, along with an October 2026 preliminary file and the corresponding NDC-HCPCS crosswalk resources.

That means a practice should verify the payment file that applies to the date of service rather than using a January amount for the entire year.

Quarterly updates can affect:

  • Drug payment limits
  • NDC-HCPCS crosswalks
  • NOC pricing information
  • Other technical billing resources

CMS also reminds providers through its ASP billing resources that units billed should not exceed what is supported by the code descriptor, reporting instructions, and applicable national or local policy.

MedIntelHub’s monthly healthcare update review checklist provides a broader process for checking code, payer, fee-schedule, and denial changes throughout the year.

Practical J3301 Billing Examples

The following examples are intentionally simplified. They show how claim logic works; they do not replace product labeling, clinical judgment, current CPT guidance, NCCI edits, or payer-specific policy.

Example 1: 40 mg Joint Injection

A physician documents administration of 40 mg triamcinolone acetonide during a major-joint injection. The exact product is appropriate for J3301.

Drug calculation:

40 mg / 10 mg = 4 units of J3301.

The joint-injection procedure is coded separately when supported. The diagnosis should reflect the condition treated.

Example 2: 20 mg Intralesional Injection

A patient receives 20 mg of a triamcinolone acetonide formulation labeled for intralesional use.

20 mg / 10 mg = 2 units of J3301.

The drug claim quantity does not depend on the number of lesions. The intralesional procedure service may have its own coding logic based on the number of lesions treated.

Example 3: 10 mg Dose From a 40 mg/mL Product

The clinician administers 0.25 mL of a 40 mg/mL product.

0.25 mL x 40 mg/mL = 10 mg.

10 mg / 10 mg per J3301 unit = 1 unit.

The small volume does not make the claim quantity 0.25. The HCPCS unit is based on milligrams.

Example 4: Single-Dose Vial With Waste

A 40 mg single-dose vial is opened. The patient receives 30 mg and 10 mg is discarded.

Administered amount: 30 mg = 3 J3301 units.

Discarded amount: 10 mg = 1 J3301 unit with JW, if Medicare’s discarded-drug policy applies to that product and setting.

Example 5: Single-Dose Vial With No Waste

A qualifying 40 mg single-dose vial is used and the full 40 mg is administered.

40 mg = 4 J3301 units.

If no drug is discarded, JZ may be required under Medicare’s single-dose-container policy.

Example 6: Multiple-Dose Vial

A practice uses a 40 mg/mL multiple-dose vial and administers 20 mg.

20 mg = 2 J3301 units.

The single-dose-container JW/JZ requirement should not be applied automatically merely because the same HCPCS code is being billed.

Common J3301 Billing Errors

Reporting One Unit for Every Injection

The number of injections is not the J3301 billing quantity. Units are based on the total milligrams represented by the code descriptor.

Reporting Milliliters as HCPCS Units

A 1 mL injection can represent one, four, or another number of units depending on concentration and the HCPCS descriptor. Convert the documented dose to milligrams first.

Choosing J3301 Without Identifying the Product

Triamcinolone products are not all reported with J3301. Preservative-free, extended-release, ophthalmic, and other formulations may have different HCPCS codes.

Adding JW or JZ Without Checking the Package

The package type matters. A single-dose vial and multiple-dose vial can contain the same concentration but have different discarded-drug modifier implications.

Billing the Drug but Not the Administration Service

Sometimes the drug is captured while the injection procedure is missed. The opposite can also happen. Charge capture should account for both components when each is separately reportable.

Using the Wrong Administration Code

An intramuscular injection, a joint injection, and an intralesional injection are different services. A default administration code can create an inaccurate claim.

Missing Dose Documentation

If the note gives the product name but not the milligrams administered, the billing team cannot reliably calculate J3301 units.

Hard-Coding an Old Medicare Price

Medicare Part B payment-limit files are updated quarterly. A stale fee table can produce incorrect expected reimbursement and misleading underpayment reports.

Common Reasons J3301 Claims Are Denied or Paid Incorrectly

A J3301 claim can fail even when the code itself is valid.

Common areas to investigate include:

  • Incorrect units
  • Product not matching J3301
  • Diagnosis not supporting medical necessity
  • Administration code missing or inconsistent with the documented route
  • Payer-specific authorization or frequency limits
  • Unsupported JW/JZ modifier
  • Missing discarded-drug line
  • Missing JZ when required for a qualifying single-dose package
  • NDC mismatch when the payer requires NDC reporting
  • NCCI or payer edit involving the administration service
  • Duplicate billing
  • Place-of-service or provider-enrollment issues
  • Fee schedule or drug-pricing file not updated for the date of service

If the remittance does not match expectations, start with the actual denial or adjustment reason rather than changing the code immediately.

A Practical J3301 Pre-Bill Checklist

Before the claim is released, confirm:

  1. What exact triamcinolone product was administered?
  2. Does J3301 match that formulation, or is a more specific HCPCS code available?
  3. How many milligrams were actually administered?
  4. How many J3301 units does that dose represent?
  5. Is the concentration documented clearly enough to support the calculation?
  6. What route and anatomical site were used?
  7. Is the appropriate administration or procedure service documented?
  8. Does the diagnosis support the treatment and payer medical-necessity requirements?
  9. Does the payer require an NDC on the claim?
  10. Was the drug supplied from a single-dose or multiple-dose container?
  11. If it was single-dose, was any medication discarded?
  12. Does JW or JZ apply under current Medicare rules?
  13. Are the drug and procedure code combination consistent with current NCCI and payer edits?
  14. Is the correct current-quarter Medicare drug payment file loaded for expected reimbursement?

Frequently Asked Questions About J3301

What does J3301 mean?

J3301 is a HCPCS Level II code for triamcinolone acetonide injection, not otherwise specified, billed in 10 mg units.

Is J3301 a CPT code?

No. It is a HCPCS Level II drug code. The phrase “CPT code J3301” is common in online searches but technically inaccurate.

How many units is 40 mg of J3301?

Four units, assuming J3301 correctly describes the drug. Each unit represents 10 mg.

How many units is 20 mg?

Two units. Divide the documented dose in milligrams by 10.

How many units is 80 mg?

Eight units, again assuming J3301 is the correct code for the product administered.

Is 1 mL always one unit of J3301?

No. Milliliters measure volume. J3301 units are based on milligrams. One mL of a 40 mg/mL product contains 40 mg, which equals four J3301 units.

Does J3301 include the injection procedure?

No. J3301 reports the drug. The administration or procedural service is a separate coding question and may be separately reportable when supported.

Can J3301 be billed with 96372?

Potentially, when the documented medication is administered intramuscularly or subcutaneously and 96372 is the appropriate administration service under current CPT and payer rules. The product’s labeled route must also support the administration performed.

Can J3301 be billed with a joint injection code?

Yes, when J3301 correctly represents the drug used and the joint injection is separately reportable. The procedure code depends on the joint and whether image guidance is part of the reported service.

Does J3301 always require JW or JZ?

No. Medicare’s JW/JZ rules apply to qualifying separately payable Part B drugs from single-dose containers or single-use packages. Some triamcinolone acetonide products are supplied in multiple-dose vials, so package type must be checked.

What is the difference between JW and JZ?

JW identifies a discarded amount from a qualifying single-dose container or single-use package. JZ attests that no amount was discarded from such a package when Medicare’s policy applies.

Can J3301 be used for Kenalog-40?

J3301 may be appropriate for certain triamcinolone acetonide products that match its descriptor, but billing should be based on the exact product, formulation, package, and current HCPCS file rather than the brand name alone.

Can J3301 be used for Kenalog-10?

The same principle applies. Identify the exact product and current HCPCS mapping. KENALOG-10 is a 10 mg/mL formulation labeled for intra-articular or intralesional use only, so route documentation also matters.

Does Medicare require the NDC for J3301?

Do not assume one universal rule. NDC reporting requirements vary by payer and claim type. Some Medicaid and commercial plans require NDC information. Verify the payer’s current instructions.

Does the Medicare payment amount for J3301 stay the same all year?

Not necessarily. CMS publishes Medicare Part B drug payment-limit files quarterly. The applicable file should be checked for the date of service.

What Matters Most When Billing J3301

J3301 is easy to recognize and easy to miscalculate.

The code is built around a 10 mg billing increment. Once that is understood, the drug quantity becomes a dose-conversion problem rather than a vial-counting exercise. A 40 mg dose is four units whether it came from 1 mL of a 40 mg/mL product or another volume that delivered the same total milligrams.

The more difficult part is everything around the number. The exact triamcinolone product must match J3301. The route and site determine the administration service. The diagnosis has to support the treatment. The payer may require an NDC. And Medicare’s JW/JZ rules depend on whether the medication came from a qualifying single-dose package rather than a multiple-dose vial.

For 2026 claims, practices should also keep current-quarter Medicare Part B drug pricing and crosswalk files in their billing workflow. A correct claim can still look underpaid if the expected reimbursement table is stale.

A reliable process starts with the medication record, not the charge screen: identify the product, confirm the administered milligrams, calculate HCPCS units, verify the administration service, then apply package-specific waste rules and payer requirements.

Resources

Centers for Medicare & Medicaid Services – Medicare Part B Drug Payment Limit Files

CMS publishes quarterly Part B drug payment-limit files and NDC-HCPCS crosswalks used for current Medicare drug pricing.

CMS: Medicare Part B Drug Payment Limit Files

Centers for Medicare & Medicaid Services – ASP Billing Resources

CMS provides billing resources for Part B drugs, including guidance on units and links to JW/JZ modifier policy materials.

CMS: ASP Billing Resources

Centers for Medicare & Medicaid Services – Discarded Drugs

CMS explains Medicare’s discarded-drug policy and how JW and JZ identify discarded amounts or attest that no amount was discarded from qualifying single-dose packages.

CMS: Discarded Drugs

DailyMed – KENALOG-10 Injection

The FDA labeling available through DailyMed describes the 10 mg/mL triamcinolone acetonide formulation and its labeled intra-articular and intralesional routes.

DailyMed: KENALOG-10 Injection

DailyMed – Triamcinolone Acetonide Injectable Suspension 40 mg/mL

DailyMed lists current 40 mg/mL package configurations, including examples of 1 mL single-dose vials and 5 mL or 10 mL multiple-dose vials.

DailyMed: Triamcinolone Acetonide Injectable Suspension

Centers for Medicare & Medicaid Services Data – J3301 Descriptor

CMS’s Medicare Physician and Other Practitioner data tool displays J3301 as triamcinolone acetonide injection, not otherwise specified, 10 mg.

CMS Data: Medicare Physician & Other Practitioner Look-up Tool

Editorial Guidelines & Medical Disclaimer

This article is for general educational and medical-billing information. It does not recommend a triamcinolone product, dose, injection route, or treatment plan for an individual patient. Drug selection, dosing, administration, contraindications, and monitoring belong to the treating healthcare professional and should follow the current product labeling and clinical circumstances.

Coding and reimbursement requirements can change. Before submitting a claim, verify the current HCPCS code set, CPT administration rules, Medicare or payer policy, NCCI edits, product labeling, package type, applicable NDC requirements, and the Medicare Part B drug payment file for the date of service. A valid code does not guarantee coverage or payment.

JW and JZ use is especially package-dependent. Do not apply either modifier simply because the claim contains J3301. Confirm whether the drug was furnished from a qualifying single-dose container or single-use package and whether any amount was discarded.

MedIntelHub develops medical and billing content from authoritative sources and reviews it for accuracy and clarity. Readers can review our Editorial Policy for information about sourcing, updates, and corrections.

David Bennett

David Bennett is an author at MedIntelHub, where he creates clear, practical, and well-researched content about healthcare, medical billing, insurance, and patient education. His goal is to make complex healthcare topics easier for readers to understand and use in everyday situations. David emphasizes accuracy, transparency, and reliable sourcing, using information from trusted organizations and official healthcare resources whenever possible. Content published by David is intended for educational purposes and should not replace advice from qualified medical, legal, or healthcare professionals.

Leave a Reply

Your email address will not be published. Required fields are marked *